{"title":"Antipsychotic \/ Mood   \n2nd Generation","description":null,"products":[{"product_id":"abilify","title":"Abilify","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549524053,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_82e324b3-49c5-4d5c-ba14-18516c38fdf8.jpg?v=1647711278"},{"product_id":"abilify-discmelt-discontinued","title":"Abilify Discmelt (Discontinued)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549556821,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_65c6a331-e4ac-4d05-81df-effd6230d27c.jpg?v=1647711280"},{"product_id":"abilify-maintena","title":"Abilify Maintena","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549589589,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_af512f4f-0f48-4d06-a913-2ce849662604.jpg?v=1647711282"},{"product_id":"abilify-mycite","title":"Abilify MyCite","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549622357,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_44e9e172-6e85-472c-83f1-707a2afeb3d0.jpg?v=1647711285"},{"product_id":"aripiprazole-generic","title":"Aripiprazole (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549655125,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_c9d6326f-0356-4ead-824a-0e6ad2de752d.jpg?v=1647711287"},{"product_id":"aristada","title":"Aristada","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole Lauroxil \u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole Lauroxil  \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549687893,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_496c8d79-7ca9-41ec-ad9b-306bbda65669.jpg?v=1647711289"},{"product_id":"aristada-initio","title":"Aristada Initio","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole Lauroxil \u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole Lauroxil  \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549720661,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_3a65282e-0981-45d7-a7d7-754759ddec3a.jpg?v=1647711291"},{"product_id":"aripiprazole-lauroxil-generic","title":"Aripiprazole Lauroxil (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole Lauroxil \u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole Lauroxil  \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549753429,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_594f9862-63c0-411c-86f3-faa061bb381c.jpg?v=1647711293"},{"product_id":"rexulti","title":"Rexulti","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 72% of people taking 1st generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)] \u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Brexpiprazole\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Brexpiprazole \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549818965,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_d9950327-996f-4309-8ced-c7746ecaa381.jpg?v=1647711295"},{"product_id":"brexpiprazole-generic","title":"Brexpiprazole (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 72% of people taking 1st generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)] \u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Brexpiprazole\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Brexpiprazole \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549851733,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_2093ce2c-f3d3-4c99-b70a-6d73090b6bf8.jpg?v=1647711297"},{"product_id":"vraylar","title":"Vraylar","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ Greater than 7% weight gain in 8.5% of people if dose is 1.5 mg per day (1557, 1560)\u003cbr\u003e\n↑ Greater than 7% weight gain in 10.7% of people if dose is 3 mg per day (1557, 1560)\u003cbr\u003e\n↑ Greater than 7% weight gain in 4.9% of people if dose is 4.5 mg per day (1557, 1560)\u003cbr\u003e\n↑ Greater than 7% weight gain in 33% of people if dose is 4.5 mg per day in 48 weeks (1557, 1559)\u003cbr\u003e\n↑ Greater than 7% weight gain in 12% of people on average in 48 week study (1557, 1559)\u003cbr\u003e\n↓ Greater than 7% weight loss in 8% of people if dose is 4.5 mg per day in 48 weeks (1557, 1559)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 12 to 35 adults taking Cariprazine (1557, 1560)\u003cbr\u003e\n↑ If 12 to 35 people take Cariprazine (Vraylar) at least one will experience greater than 7% weight gain. (1557)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Cariprazine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Cariprazine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549884501,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_416dfa27-cbb9-4ca5-bcd7-5261994f59b1.jpg?v=1647711299"},{"product_id":"cariprazine-generic","title":"Cariprazine (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ Greater than 7% weight gain in 8.5% of people if dose is 1.5 mg per day (1557, 1560)\u003cbr\u003e\n↑ Greater than 7% weight gain in 10.7% of people if dose is 3 mg per day (1557, 1560)\u003cbr\u003e\n↑ Greater than 7% weight gain in 4.9% of people if dose is 4.5 mg per day (1557, 1560)\u003cbr\u003e\n↑ Greater than 7% weight gain in 33% of people if dose is 4.5 mg per day in 48 weeks (1557, 1559)\u003cbr\u003e\n↑ Greater than 7% weight gain in 12% of people on average in 48 week study (1557, 1559)\u003cbr\u003e\n↓ Greater than 7% weight loss in 8% of people if dose is 4.5 mg per day in 48 weeks (1557, 1559)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 12 to 35 adults taking Cariprazine (1557, 1560)\u003cbr\u003e\n↑ If 12 to 35 people take Cariprazine (Vraylar) at least one will experience greater than 7% weight gain. (1557)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Cariprazine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Cariprazine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549917269,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_d4f9271e-942d-401c-91d5-25d7fe46c4d9.jpg?v=1647711301"},{"product_id":"clozaril","title":"Clozaril","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 9.79 pounds average in 10 wks [Meta-analysis of 81 studies (67)] and (28) \u003cbr\u003e\n↑ 11.66 to 16.94 pounds in 6 months - 1 year (30)\u003cbr\u003e\n↑ 9.24 pounds average in 14 weeks (162)\u003cbr\u003e\n↑ 3.74 pounds per month. [(Systematic review of 34 years of literature (4)] \u003cbr\u003e\n↑ 21.78 pounds average in 52 months (159)\u003cbr\u003e\n↑ 48% of people taking Clozapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 1.98 to 20.9 pounds in youths taking clozapine (Clozaril) (n=97 youth) (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) children and adolescents. Results of 34 head-to-head \u0026amp; placebo controlled trials (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 controlled trials. (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Clozapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Clozapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979549950037,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_971d6909-31f1-4022-a28c-c33a2e797135.jpg?v=1647711303"},{"product_id":"fazaclo-discontinued","title":"FazaClo (Discontinued)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 9.79 pounds average in 10 wks [Meta-analysis of 81 studies (67)] and (28) \u003cbr\u003e\n↑ 11.66 to 16.94 pounds in 6 months - 1 year (30)\u003cbr\u003e\n↑ 9.24 pounds average in 14 weeks (162)\u003cbr\u003e\n↑ 3.74 pounds per month. [(Systematic review of 34 years of literature (4)] \u003cbr\u003e\n↑ 21.78 pounds average in 52 months (159)\u003cbr\u003e\n↑ 48% of people taking Clozapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 1.98 to 20.9 pounds in youths taking clozapine (Clozaril) (n=97 youth) (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) children and adolescents. Results of 34 head-to-head \u0026amp; placebo controlled trials (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 controlled trials. (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Clozapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Clozapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550015573,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_5df7ca28-fe07-4cbf-98fc-5d40790c5048.jpg?v=1647711305"},{"product_id":"versacloz","title":"Versacloz","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 9.79 pounds average in 10 wks [Meta-analysis of 81 studies (67)] and (28) \u003cbr\u003e\n↑ 11.66 to 16.94 pounds in 6 months - 1 year (30)\u003cbr\u003e\n↑ 9.24 pounds average in 14 weeks (162)\u003cbr\u003e\n↑ 3.74 pounds per month. [(Systematic review of 34 years of literature (4)] \u003cbr\u003e\n↑ 21.78 pounds average in 52 months (159)\u003cbr\u003e\n↑ 48% of people taking Clozapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 1.98 to 20.9 pounds in youths taking clozapine (Clozaril) (n=97 youth) (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) children and adolescents. Results of 34 head-to-head \u0026amp; placebo controlled trials (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 controlled trials. (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Clozapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Clozapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550048341,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_8c26845a-7322-4b1e-b8a6-1f270e9ab97c.jpg?v=1647711307"},{"product_id":"clozapine-generic","title":"Clozapine (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 9.79 pounds average in 10 wks [Meta-analysis of 81 studies (67)] and (28) \u003cbr\u003e\n↑ 11.66 to 16.94 pounds in 6 months - 1 year (30)\u003cbr\u003e\n↑ 9.24 pounds average in 14 weeks (162)\u003cbr\u003e\n↑ 3.74 pounds per month. [(Systematic review of 34 years of literature (4)] \u003cbr\u003e\n↑ 21.78 pounds average in 52 months (159)\u003cbr\u003e\n↑ 48% of people taking Clozapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 1.98 to 20.9 pounds in youths taking clozapine (Clozaril) (n=97 youth) (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) children and adolescents. Results of 34 head-to-head \u0026amp; placebo controlled trials (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 controlled trials. (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Clozapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Clozapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550146645,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_710a32a4-8fd9-4670-b445-14ec1a45137f.jpg?v=1647711309"},{"product_id":"fanapt","title":"Fanapt","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 5.72 pounds average in less than \u0026lt; 6 wk, (n = 1239, sd = 3.7) in study for Schizophrenia (245)\u003cbr\u003e\n↑ 3.3 to 4.62 pounds in 6 weeks in study for Schizophrenia (198) \u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 12 adults taking Iloperidone (1557, 1560)\u003cbr\u003e\n↑ If 12 people take Iloperidone at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Iloperidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Iloperidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550179413,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_ab7e7da7-b18e-45a4-b957-6235699880c6.jpg?v=1647711311"},{"product_id":"fanapt-titration-pack","title":"Fanapt Titration Pack","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 5.72 pounds average in less than \u0026lt; 6 wk, (n = 1239, sd = 3.7) in study for Schizophrenia (245)\u003cbr\u003e\n↑ 3.3 to 4.62 pounds in 6 weeks in study for Schizophrenia (198) \u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 12 adults taking Iloperidone (1557, 1560)\u003cbr\u003e\n↑ If 12 people take Iloperidone at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Iloperidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Iloperidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550212181,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_0b6fe0e0-fb1c-4c1a-8a7e-94c8add72f12.jpg?v=1647711313"},{"product_id":"iloperidone-generic","title":"Iloperidone (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 5.72 pounds average in less than \u0026lt; 6 wk, (n = 1239, sd = 3.7) in study for Schizophrenia (245)\u003cbr\u003e\n↑ 3.3 to 4.62 pounds in 6 weeks in study for Schizophrenia (198) \u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 12 adults taking Iloperidone (1557, 1560)\u003cbr\u003e\n↑ If 12 people take Iloperidone at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Iloperidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Iloperidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550244949,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_09e565fd-b924-45a5-818f-4cd7651b885e.jpg?v=1647711315"},{"product_id":"latuda","title":"Latuda","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.98 pounds in \u0026lt;6 wk, n = 90 (56)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 67 adults taking Lurasidone (1557, 1560)\u003cbr\u003e\n↑ If 67 people take Lurasidone at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Lurasidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Lurasidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550376021,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_8e80277b-8c83-4542-b5b6-63d7357615f9.jpg?v=1647711318"},{"product_id":"lurasidone-generic","title":"Lurasidone (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.98 pounds in \u0026lt;6 wk, n = 90 (56)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 67 adults taking Lurasidone (1557, 1560)\u003cbr\u003e\n↑ If 67 people take Lurasidone at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Lurasidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Lurasidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550408789,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_474b3a2a-e99f-46fc-8586-2d19deb214f3.jpg?v=1647711320"},{"product_id":"invega","title":"Invega","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.32 lb 3 and 6mg\/day doses in 6 weeks Schizophrenia study (195) \u003cbr\u003e\n↑ 2.2 lb 9mg\/day dose in 6 weeks Schizophrenia study (195); \u003cbr\u003e\n↑ 2.42 pounds 12mg\/day dose in 6 weeks Schizophrenia study (195) \u003cbr\u003e\n↑ 4.18 pounds 15mg\/day dose in 6 weeks Schizophrenia study (195)\u003cbr\u003e\n↑ Weight gain of less than less than \u0026lt; 4.4 pounds in 6 weeks (68)\u003cbr\u003e\n↑ 14 % of people gain 7% or \u0026gt; greater of their baseline  weight  in greater than \u0026gt; 38 weeks p\u0026lt;0.001 in study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Paliperidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Paliperidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550441557,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_0900c98c-ae55-4efc-a16b-95439c24ed8a.jpg?v=1647711322"},{"product_id":"invega-hafyera","title":"Invega Hafyera","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.32 lb 3 and 6mg\/day doses in 6 weeks Schizophrenia study (195) \u003cbr\u003e\n↑ 2.2 lb 9mg\/day dose in 6 weeks Schizophrenia study (195); \u003cbr\u003e\n↑ 2.42 pounds 12mg\/day dose in 6 weeks Schizophrenia study (195) \u003cbr\u003e\n↑ 4.18 pounds 15mg\/day dose in 6 weeks Schizophrenia study (195)\u003cbr\u003e\n↑ Weight gain of less than less than \u0026lt; 4.4 pounds in 6 weeks (68)\u003cbr\u003e\n↑ 14 % of people gain 7% or \u0026gt; greater of their baseline  weight  in greater than \u0026gt; 38 weeks p\u0026lt;0.001 in study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Paliperidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Paliperidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550474325,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_404be4ee-c53d-460a-923e-d7463775e4ac.jpg?v=1647711324"},{"product_id":"invega-sustenna","title":"Invega Sustenna","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.32 lb 3 and 6mg\/day doses in 6 weeks Schizophrenia study (195) \u003cbr\u003e\n↑ 2.2 lb 9mg\/day dose in 6 weeks Schizophrenia study (195); \u003cbr\u003e\n↑ 2.42 pounds 12mg\/day dose in 6 weeks Schizophrenia study (195) \u003cbr\u003e\n↑ 4.18 pounds 15mg\/day dose in 6 weeks Schizophrenia study (195)\u003cbr\u003e\n↑ Weight gain of less than less than \u0026lt; 4.4 pounds in 6 weeks (68)\u003cbr\u003e\n↑ 14 % of people gain 7% or \u0026gt; greater of their baseline  weight  in greater than \u0026gt; 38 weeks p\u0026lt;0.001 in study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Paliperidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Paliperidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550507093,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_9474c8e0-7c69-4e04-a87b-8bff6f4d0993.jpg?v=1647711326"},{"product_id":"invega-trinza","title":"Invega Trinza","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.32 lb 3 and 6mg\/day doses in 6 weeks Schizophrenia study (195) \u003cbr\u003e\n↑ 2.2 lb 9mg\/day dose in 6 weeks Schizophrenia study (195); \u003cbr\u003e\n↑ 2.42 pounds 12mg\/day dose in 6 weeks Schizophrenia study (195) \u003cbr\u003e\n↑ 4.18 pounds 15mg\/day dose in 6 weeks Schizophrenia study (195)\u003cbr\u003e\n↑ Weight gain of less than less than \u0026lt; 4.4 pounds in 6 weeks (68)\u003cbr\u003e\n↑ 14 % of people gain 7% or \u0026gt; greater of their baseline  weight  in greater than \u0026gt; 38 weeks p\u0026lt;0.001 in study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Paliperidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Paliperidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550539861,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_45453216-30f1-43e3-91c1-36dad9240186.jpg?v=1647711328"},{"product_id":"paliperidone-generic","title":"Paliperidone (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.32 lb 3 and 6mg\/day doses in 6 weeks Schizophrenia study (195) \u003cbr\u003e\n↑ 2.2 lb 9mg\/day dose in 6 weeks Schizophrenia study (195); \u003cbr\u003e\n↑ 2.42 pounds 12mg\/day dose in 6 weeks Schizophrenia study (195) \u003cbr\u003e\n↑ 4.18 pounds 15mg\/day dose in 6 weeks Schizophrenia study (195)\u003cbr\u003e\n↑ Weight gain of less than less than \u0026lt; 4.4 pounds in 6 weeks (68)\u003cbr\u003e\n↑ 14 % of people gain 7% or \u0026gt; greater of their baseline  weight  in greater than \u0026gt; 38 weeks p\u0026lt;0.001 in study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Paliperidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Paliperidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550572629,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_cc497485-075a-47c1-98da-fc8bc0dbdaaf.jpg?v=1647711330"},{"product_id":"nuplazid","title":"Nuplazid","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\nAddition of Pimavanserin  to what was predicted to be sub-effective doses of the 2nd Generation Atypical Antipsychotic Risperidone (2mg\/day) led to clinical efficacy comparable to that of full dose Risperidone, (6 mg\/day), a dose believed to be effective in the majority of non-treatment resistant schizophrenia patients, and at the same time, produced less severe weight gain, less extrapyramidal symptoms (EPS), and less serum prolactin elevations (1563, 1565)\u003cbr\u003e\nThe percentage of people who gained at least 7% in weight in this 6 week study was significantly greater in the Risperidone, (6 mg\/day) group (18.9%) compared with the Risperidone (2mg\/day) + Pimavanserin combination therapy group (6.3%); (p=0.03). (1563)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Pimavanserin\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Pimavanserin \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550703701,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_f90edebe-4294-4fdb-b35c-d5ab70cff015.jpg?v=1647711332"},{"product_id":"pimavanserin-generic","title":"Pimavanserin (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\nAddition of Pimavanserin  to what was predicted to be sub-effective doses of the 2nd Generation Atypical Antipsychotic Risperidone (2mg\/day) led to clinical efficacy comparable to that of full dose Risperidone, (6 mg\/day), a dose believed to be effective in the majority of non-treatment resistant schizophrenia patients, and at the same time, produced less severe weight gain, less extrapyramidal symptoms (EPS), and less serum prolactin elevations (1563, 1565)\u003cbr\u003e\nThe percentage of people who gained at least 7% in weight in this 6 week study was significantly greater in the Risperidone, (6 mg\/day) group (18.9%) compared with the Risperidone (2mg\/day) + Pimavanserin combination therapy group (6.3%); (p=0.03). (1563)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Pimavanserin\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Pimavanserin \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550736469,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_bc740f74-dfd6-48d5-881e-900c95e869aa.jpg?v=1647711334"},{"product_id":"antipsychotic-mood-2nd-generation-drugs","title":"Antipsychotic \/ Mood 2nd Generation Drugs","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\nA study of antipsychotic use in children and youth revealed that all of the second generation antipsychotic drugs  studied [aripiprazole (Abilify), aripiprazole lauroxil (Aristada), clozapine (Clozaril and Versacloz), quetiapine (Seroquel), ziprasidone (Geodon), olanzapine (Zyprexa), risperidone (Risperdal and Perseris)] caused significant weight gain (725) and:\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Antipsychotic \/ Mood \u003cbr\u003e\n2nd Generation Drugs\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Antipsychotic \/ Mood \n2nd Generation Drugs \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550769237,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_c3d10adf-5d3d-441d-8122-1d87e6d0d5fe.jpg?v=1647711336"},{"product_id":"seroquel","title":"Seroquel","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 2.57 pounds average per month (18) \u003cbr\u003e\n↑ 11 to 25% of people gained \u0026gt; greater than 7 % weight if taken for 6 to 8 weeks (4)\u003cbr\u003e\n↑ 25% people  gained ↑ 7 % or \u0026gt; greater weight in \u0026gt; 38 weeks if Quetiapine was the 1st antipsychotic medication taken p\u0026lt;0.001 in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 19 % of people gained ↑ 7% or more of their baseline  weight  in greater than \u0026gt; 38 weeks p\u0026lt;0.001 study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 2.42 pounds average vs placebo (no drug) (time not specified) in Meta-analysis study (700)\u003cbr\u003e\n↑ 3.96 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 5.06 to 13.42 pounds in youths taking quetiapine (Zyprexa) (n=133 youth) (725)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 9 young people taking quetiapine (Zyprexa) (725)\u003cbr\u003e\n↑ If 9 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Quetiapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Quetiapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550802005,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_2d281058-bfa5-4214-93e5-6f11337dc4ec.jpg?v=1647711338"},{"product_id":"seroquel-xr","title":"Seroquel XR","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 2.57 pounds average per month (18) \u003cbr\u003e\n↑ 11 to 25% of people gained \u0026gt; greater than 7 % weight if taken for 6 to 8 weeks (4)\u003cbr\u003e\n↑ 25% people  gained ↑ 7 % or \u0026gt; greater weight in \u0026gt; 38 weeks if Quetiapine was the 1st antipsychotic medication taken p\u0026lt;0.001 in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 19 % of people gained ↑ 7% or more of their baseline  weight  in greater than \u0026gt; 38 weeks p\u0026lt;0.001 study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 2.42 pounds average vs placebo (no drug) (time not specified) in Meta-analysis study (700)\u003cbr\u003e\n↑ 3.96 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 5.06 to 13.42 pounds in youths taking quetiapine (Zyprexa) (n=133 youth) (725)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 9 young people taking quetiapine (Zyprexa) (725)\u003cbr\u003e\n↑ If 9 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Quetiapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Quetiapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550834773,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_5e504d0e-6a94-4b52-b912-f27256d10ede.jpg?v=1647711339"},{"product_id":"quetiapine-generic","title":"Quetiapine (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 2.57 pounds average per month (18) \u003cbr\u003e\n↑ 11 to 25% of people gained \u0026gt; greater than 7 % weight if taken for 6 to 8 weeks (4)\u003cbr\u003e\n↑ 25% people  gained ↑ 7 % or \u0026gt; greater weight in \u0026gt; 38 weeks if Quetiapine was the 1st antipsychotic medication taken p\u0026lt;0.001 in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 19 % of people gained ↑ 7% or more of their baseline  weight  in greater than \u0026gt; 38 weeks p\u0026lt;0.001 study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 2.42 pounds average vs placebo (no drug) (time not specified) in Meta-analysis study (700)\u003cbr\u003e\n↑ 3.96 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 5.06 to 13.42 pounds in youths taking quetiapine (Zyprexa) (n=133 youth) (725)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 9 young people taking quetiapine (Zyprexa) (725)\u003cbr\u003e\n↑ If 9 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Quetiapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Quetiapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550867541,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_97451ec9-09ae-4a48-90c1-797496bc5f31.jpg?v=1647711341"},{"product_id":"geodon","title":"Geodon","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 0.09 pounds average over 10 weeks [Meta-analysis of 81 studies (67)] and (24)\u003cbr\u003e\n↑ 1.76 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↓ 5.94 pounds average over 52 weeks if 40 mg per day for Schizophrenia (170)\u003cbr\u003e\n↓ 7.04 pounds average over 52 weeks if 80 mg per day for Schizophrenia (170) \u003cbr\u003e\n↓ 6.38 pounds average over 52 weeks if 160 mg per day for Schizophrenia (170)  \u003cbr\u003e\n↑ 8 % of people gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 17 adults taking Ziprasidone (Geodon) (1557)\u003cbr\u003e\n↑ If 17 people take Ziprasidone at least one will (1557)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for youth 7% weight gain is 36 youth taking Ziprasidone (Geodon) (725)\u003cbr\u003e\n↑ If 36 Youth take Ziprasidone at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth. Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)\u003cbr\u003e\nGeneric Name:  Ziprasidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Ziprasidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550900309,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_470ab81c-a03d-4262-a3d1-415f44010229.jpg?v=1647711343"},{"product_id":"ziprasidone-generic","title":"Ziprasidone (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 0.09 pounds average over 10 weeks [Meta-analysis of 81 studies (67)] and (24)\u003cbr\u003e\n↑ 1.76 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↓ 5.94 pounds average over 52 weeks if 40 mg per day for Schizophrenia (170)\u003cbr\u003e\n↓ 7.04 pounds average over 52 weeks if 80 mg per day for Schizophrenia (170) \u003cbr\u003e\n↓ 6.38 pounds average over 52 weeks if 160 mg per day for Schizophrenia (170)  \u003cbr\u003e\n↑ 8 % of people gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 17 adults taking Ziprasidone (Geodon) (1557)\u003cbr\u003e\n↑ If 17 people take Ziprasidone at least one will (1557)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for youth 7% weight gain is 36 youth taking Ziprasidone (Geodon) (725)\u003cbr\u003e\n↑ If 36 Youth take Ziprasidone at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth. Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)\u003cbr\u003e\nGeneric Name:  Ziprasidone\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Ziprasidone \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550933077,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_45b1a6ea-ae5c-412b-956e-d629f97ca39e.jpg?v=1647711345"},{"product_id":"saphris","title":"Saphris","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.98 pounds average in 3 weeks (197)\u003cbr\u003e\n↑ average gain of 7% above baseline weight in 3 weeks (197)\u003cbr\u003e\n↑ 23% of people taking Asenapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 35 adults taking Asenapine (Saphris) (1557)\u003cbr\u003e\n↑ If 35 people take Asenapine at least one will experience greater than 7% weight gain. (1557)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Asenapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Asenapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979550965845,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_d1b5a411-6e0f-42af-8fec-a34d2520072f.jpg?v=1647711347"},{"product_id":"secuado","title":"Secuado","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.98 pounds average in 3 weeks (197)\u003cbr\u003e\n↑ average gain of 7% above baseline weight in 3 weeks (197)\u003cbr\u003e\n↑ 23% of people taking Asenapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 35 adults taking Asenapine (Saphris) (1557)\u003cbr\u003e\n↑ If 35 people take Asenapine at least one will experience greater than 7% weight gain. (1557)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Asenapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Asenapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551031381,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_d49544c3-2637-49b1-84af-de45c55fcefc.jpg?v=1647711349"},{"product_id":"asenapine-generic","title":"Asenapine (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.98 pounds average in 3 weeks (197)\u003cbr\u003e\n↑ average gain of 7% above baseline weight in 3 weeks (197)\u003cbr\u003e\n↑ 23% of people taking Asenapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 35 adults taking Asenapine (Saphris) (1557)\u003cbr\u003e\n↑ If 35 people take Asenapine at least one will experience greater than 7% weight gain. (1557)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Asenapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Asenapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551096917,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_1a288869-355e-4d2f-a46f-05464ed912e4.jpg?v=1647711351"},{"product_id":"zyprexa","title":"Zyprexa","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 15.62 to 20.24 pounds in short term studies in people who had not taken antipsychotic therapy before. (220)\u003cbr\u003e\n↑ 22.44 to 33.88 pounds in long term studies. [Systematic critical reappraisal (220)]\u003cbr\u003e\n↑ 5.05 pounds per month [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 16.06 pounds average in 12 weeks in a study for Psychosis (196) ↑ 61.5% of people gain \u0026gt; greater than 7% baseline weight in 12 weeks in a study for Psychosis (196) ↑ 9.13 pounds average in 10 weeks study for use in Psychosis and Bipolar (28) \u003cbr\u003e\n↑ 2 pounds per month in large study of 1493 patients with schitzophrenia who had taken antipsychotic therapies previously. [Large study (2220)]\u003cbr\u003e\n↑ 9.02 to 26.4 pounds in 6 months to 1 year study for use in Psychosis and Bipolar (28)\u003cbr\u003e\n↑ 9.13 pounds average in 10 weeks [Meta-analysis of 81 studies (67)] \u003cbr\u003e\n↑ 8.58 pounds average in 12 weeks in study for Bipolar (160) ↑ 5.28 lbs. Meta-analysis over varying times (700)\u003cbr\u003e\n↑ 15.62 pounds average in 12 weeks in study for Psychosis (196)\u003cbr\u003e\n↑ 11.88 pounds average in 14 weeks in study for Schizo-affective disorder (162)\u003cbr\u003e\n↑ 6.16 pounds average in 24 weeks in study for borderline personality disorder  (163)\u003cbr\u003e\n↑ 8.14 pounds average in 12 weeks in study for personality disorder (166) ↑ 6.16 pounds average in 24 weeks in study for Acute mania (155) ↑ 9.46 pounds average in 12 weeks in study for Alcohol dependence (165)\u003cbr\u003e\n↑ 9.24 lbs. avg. in 26 weeks for Schizophrenia (167) ↑ 8.58 lbs. avg. in 26 weeks in study for Schizophrenia (168)\u003cbr\u003e\n↑ 8.6 to 35.64 pounds in youths taking olanzapine (Zyprexa) (n=353 youth) (725)\u003cbr\u003e\n↑ 55% people  gained↑ 7 % or \u0026gt; greater weight in first 6 weeks of therapy if Quetiapine was the 1st antipsychotic medication taken (p 0.009) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 41% of people taking Olanzapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain in Youth with Psychotic and Bipolar Disorders is 3 young people taking olanzapine (Zyprexa) (725)\u003cbr\u003e\n↑ If 3 Youth take Olanzapine at least one will experience greater than 7% weight gain.  (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725) ↑ 55% people gain ↑ 7% or greater weight in less than 6 weeks if is 1st antipsychotic drug taken p\u0026lt;0.009 study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)\u003cbr\u003e\nGeneric Name:  Olanzapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Olanzapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551129685,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_75f0aac9-37b0-4f04-97fd-ad95a17ec3cd.jpg?v=1647711354"},{"product_id":"zyprexa-relprevv","title":"Zyprexa Relprevv","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 15.62 to 20.24 pounds in short term studies in people who had not taken antipsychotic therapy before. (220)\u003cbr\u003e\n↑ 22.44 to 33.88 pounds in long term studies. [Systematic critical reappraisal (220)]\u003cbr\u003e\n↑ 5.05 pounds per month [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 16.06 pounds average in 12 weeks in a study for Psychosis (196) ↑ 61.5% of people gain \u0026gt; greater than 7% baseline weight in 12 weeks in a study for Psychosis (196) ↑ 9.13 pounds average in 10 weeks study for use in Psychosis and Bipolar (28) \u003cbr\u003e\n↑ 2 pounds per month in large study of 1493 patients with schitzophrenia who had taken antipsychotic therapies previously. [Large study (2220)]\u003cbr\u003e\n↑ 9.02 to 26.4 pounds in 6 months to 1 year study for use in Psychosis and Bipolar (28)\u003cbr\u003e\n↑ 9.13 pounds average in 10 weeks [Meta-analysis of 81 studies (67)] \u003cbr\u003e\n↑ 8.58 pounds average in 12 weeks in study for Bipolar (160) ↑ 5.28 lbs. Meta-analysis over varying times (700)\u003cbr\u003e\n↑ 15.62 pounds average in 12 weeks in study for Psychosis (196)\u003cbr\u003e\n↑ 11.88 pounds average in 14 weeks in study for Schizo-affective disorder (162)\u003cbr\u003e\n↑ 6.16 pounds average in 24 weeks in study for borderline personality disorder  (163)\u003cbr\u003e\n↑ 8.14 pounds average in 12 weeks in study for personality disorder (166) ↑ 6.16 pounds average in 24 weeks in study for Acute mania (155) ↑ 9.46 pounds average in 12 weeks in study for Alcohol dependence (165)\u003cbr\u003e\n↑ 9.24 lbs. avg. in 26 weeks for Schizophrenia (167) ↑ 8.58 lbs. avg. in 26 weeks in study for Schizophrenia (168)\u003cbr\u003e\n↑ 8.6 to 35.64 pounds in youths taking olanzapine (Zyprexa) (n=353 youth) (725)\u003cbr\u003e\n↑ 55% people  gained↑ 7 % or \u0026gt; greater weight in first 6 weeks of therapy if Quetiapine was the 1st antipsychotic medication taken (p 0.009) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 41% of people taking Olanzapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain in Youth with Psychotic and Bipolar Disorders is 3 young people taking olanzapine (Zyprexa) (725)\u003cbr\u003e\n↑ If 3 Youth take Olanzapine at least one will experience greater than 7% weight gain.  (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725) ↑ 55% people gain ↑ 7% or greater weight in less than 6 weeks if is 1st antipsychotic drug taken p\u0026lt;0.009 study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)\u003cbr\u003e\nGeneric Name:  Olanzapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Olanzapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551162453,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_ccdf19c1-5293-4669-8354-dbf392125884.jpg?v=1647711356"},{"product_id":"zyprexa-zydis","title":"Zyprexa Zydis","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 15.62 to 20.24 pounds in short term studies in people who had not taken antipsychotic therapy before. (220)\u003cbr\u003e\n↑ 22.44 to 33.88 pounds in long term studies. [Systematic critical reappraisal (220)]\u003cbr\u003e\n↑ 5.05 pounds per month [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 16.06 pounds average in 12 weeks in a study for Psychosis (196) ↑ 61.5% of people gain \u0026gt; greater than 7% baseline weight in 12 weeks in a study for Psychosis (196) ↑ 9.13 pounds average in 10 weeks study for use in Psychosis and Bipolar (28) \u003cbr\u003e\n↑ 2 pounds per month in large study of 1493 patients with schitzophrenia who had taken antipsychotic therapies previously. [Large study (2220)]\u003cbr\u003e\n↑ 9.02 to 26.4 pounds in 6 months to 1 year study for use in Psychosis and Bipolar (28)\u003cbr\u003e\n↑ 9.13 pounds average in 10 weeks [Meta-analysis of 81 studies (67)] \u003cbr\u003e\n↑ 8.58 pounds average in 12 weeks in study for Bipolar (160) ↑ 5.28 lbs. Meta-analysis over varying times (700)\u003cbr\u003e\n↑ 15.62 pounds average in 12 weeks in study for Psychosis (196)\u003cbr\u003e\n↑ 11.88 pounds average in 14 weeks in study for Schizo-affective disorder (162)\u003cbr\u003e\n↑ 6.16 pounds average in 24 weeks in study for borderline personality disorder  (163)\u003cbr\u003e\n↑ 8.14 pounds average in 12 weeks in study for personality disorder (166) ↑ 6.16 pounds average in 24 weeks in study for Acute mania (155) ↑ 9.46 pounds average in 12 weeks in study for Alcohol dependence (165)\u003cbr\u003e\n↑ 9.24 lbs. avg. in 26 weeks for Schizophrenia (167) ↑ 8.58 lbs. avg. in 26 weeks in study for Schizophrenia (168)\u003cbr\u003e\n↑ 8.6 to 35.64 pounds in youths taking olanzapine (Zyprexa) (n=353 youth) (725)\u003cbr\u003e\n↑ 55% people  gained↑ 7 % or \u0026gt; greater weight in first 6 weeks of therapy if Quetiapine was the 1st antipsychotic medication taken (p 0.009) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 41% of people taking Olanzapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain in Youth with Psychotic and Bipolar Disorders is 3 young people taking olanzapine (Zyprexa) (725)\u003cbr\u003e\n↑ If 3 Youth take Olanzapine at least one will experience greater than 7% weight gain.  (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725) ↑ 55% people gain ↑ 7% or greater weight in less than 6 weeks if is 1st antipsychotic drug taken p\u0026lt;0.009 study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)\u003cbr\u003e\nGeneric Name:  Olanzapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Olanzapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551227989,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_684148da-bb2a-4586-b3c3-53d1d33238a0.jpg?v=1647711358"},{"product_id":"olanzapine-generic","title":"Olanzapine (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 15.62 to 20.24 pounds in short term studies in people who had not taken antipsychotic therapy before. (220)\u003cbr\u003e\n↑ 22.44 to 33.88 pounds in long term studies. [Systematic critical reappraisal (220)]\u003cbr\u003e\n↑ 5.05 pounds per month [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 16.06 pounds average in 12 weeks in a study for Psychosis (196) ↑ 61.5% of people gain \u0026gt; greater than 7% baseline weight in 12 weeks in a study for Psychosis (196) ↑ 9.13 pounds average in 10 weeks study for use in Psychosis and Bipolar (28) \u003cbr\u003e\n↑ 2 pounds per month in large study of 1493 patients with schitzophrenia who had taken antipsychotic therapies previously. [Large study (2220)]\u003cbr\u003e\n↑ 9.02 to 26.4 pounds in 6 months to 1 year study for use in Psychosis and Bipolar (28)\u003cbr\u003e\n↑ 9.13 pounds average in 10 weeks [Meta-analysis of 81 studies (67)] \u003cbr\u003e\n↑ 8.58 pounds average in 12 weeks in study for Bipolar (160) ↑ 5.28 lbs. Meta-analysis over varying times (700)\u003cbr\u003e\n↑ 15.62 pounds average in 12 weeks in study for Psychosis (196)\u003cbr\u003e\n↑ 11.88 pounds average in 14 weeks in study for Schizo-affective disorder (162)\u003cbr\u003e\n↑ 6.16 pounds average in 24 weeks in study for borderline personality disorder  (163)\u003cbr\u003e\n↑ 8.14 pounds average in 12 weeks in study for personality disorder (166) ↑ 6.16 pounds average in 24 weeks in study for Acute mania (155) ↑ 9.46 pounds average in 12 weeks in study for Alcohol dependence (165)\u003cbr\u003e\n↑ 9.24 lbs. avg. in 26 weeks for Schizophrenia (167) ↑ 8.58 lbs. avg. in 26 weeks in study for Schizophrenia (168)\u003cbr\u003e\n↑ 8.6 to 35.64 pounds in youths taking olanzapine (Zyprexa) (n=353 youth) (725)\u003cbr\u003e\n↑ 55% people  gained↑ 7 % or \u0026gt; greater weight in first 6 weeks of therapy if Quetiapine was the 1st antipsychotic medication taken (p 0.009) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 41% of people taking Olanzapine gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain in Youth with Psychotic and Bipolar Disorders is 3 young people taking olanzapine (Zyprexa) (725)\u003cbr\u003e\n↑ If 3 Youth take Olanzapine at least one will experience greater than 7% weight gain.  (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725) ↑ 55% people gain ↑ 7% or greater weight in less than 6 weeks if is 1st antipsychotic drug taken p\u0026lt;0.009 study with varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)\u003cbr\u003e\nGeneric Name:  Olanzapine\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Olanzapine \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551260757,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_3f3d46ce-814f-4931-8d9b-789ff5dcf95a.jpg?v=1647711360"},{"product_id":"perseris","title":"Perseris","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 8.8 to 12.32 pounds in short term studies of people who had not taken antipsychotic therapy before. (220)\u003cbr\u003e\n↑ 14.52 to 19.58 pounds in long term studies. [Systematic critical reappraisal (220)]\u003cbr\u003e\n↑ 4.62 pounds average in 24 weeks for Schizophrenia (169)\u003cbr\u003e\n↑ 3.3 pounds average in 6 weeks for Schizophrenia (198, 199)\u003cbr\u003e\n↑ 2.2 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 28 % of people gain ↑ 7 % or more of their baseline weight in \u0026gt; greater than 38 weeks p\u0026lt;0.001 study of varied diagnoses (56)\u003cbr\u003e\n↑ 5.06 pounds average in 14 weeks for Schizo-affective disorder (162) \u003cbr\u003e\n↑ 38% people  gained ↑ 7 % or \u0026gt; greater weight in first 6 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.009) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 55% people  gained↑ 7 % or \u0026gt; greater weight in greater than \u0026gt; 38 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.008) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 4.62 pounds average in 10 weeks [Meta-analysis of 81 studies (67)] and (28) \u003cbr\u003e\n↑ 1.76 pounds average vs placebo (no drug) (time not specified) in Meta-analysis study (700)\u003cbr\u003e\n↑ 4.18 to 15.84 pounds in youths taking risperidone (Risperdal) (n=571 youth) (725)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain in Youth with Psychotic and Bipolar Disorders is 6 young people taking risperidone (Risperdal) (Results of 34 head-to-head and placebo controlled trials 725)\u003cbr\u003e\n↑ If 6 Youth take Risperidone at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Risperidone \u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Risperidone  \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551326293,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_06ee732e-8c97-42a7-a887-c28ff32fd31d.jpg?v=1647711362"},{"product_id":"risperdal","title":"Risperdal","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 8.8 to 12.32 pounds in short term studies of people who had not taken antipsychotic therapy before. (220)\u003cbr\u003e\n↑ 14.52 to 19.58 pounds in long term studies. [Systematic critical reappraisal (220)]\u003cbr\u003e\n↑ 4.62 pounds average in 24 weeks for Schizophrenia (169)\u003cbr\u003e\n↑ 3.3 pounds average in 6 weeks for Schizophrenia (198, 199)\u003cbr\u003e\n↑ 2.2 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 28 % of people gain ↑ 7 % or more of their baseline weight in \u0026gt; greater than 38 weeks p\u0026lt;0.001 study of varied diagnoses (56)\u003cbr\u003e\n↑ 5.06 pounds average in 14 weeks for Schizo-affective disorder (162) \u003cbr\u003e\n↑ 38% people  gained ↑ 7 % or \u0026gt; greater weight in first 6 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.009) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 55% people  gained↑ 7 % or \u0026gt; greater weight in greater than \u0026gt; 38 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.008) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 4.62 pounds average in 10 weeks [Meta-analysis of 81 studies (67)] and (28) \u003cbr\u003e\n↑ 1.76 pounds average vs placebo (no drug) (time not specified) in Meta-analysis study (700)\u003cbr\u003e\n↑ 4.18 to 15.84 pounds in youths taking risperidone (Risperdal) (n=571 youth) (725)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain in Youth with Psychotic and Bipolar Disorders is 6 young people taking risperidone (Risperdal) (Results of 34 head-to-head and placebo controlled trials 725)\u003cbr\u003e\n↑ If 6 Youth take Risperidone at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Risperidone \u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Risperidone  \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551359061,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_651fe102-4a50-4285-8bea-9219a2fe84e3.jpg?v=1647711364"},{"product_id":"risperdal-consta","title":"Risperdal Consta","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 8.8 to 12.32 pounds in short term studies of people who had not taken antipsychotic therapy before. (220)\u003cbr\u003e\n↑ 14.52 to 19.58 pounds in long term studies. [Systematic critical reappraisal (220)]\u003cbr\u003e\n↑ 4.62 pounds average in 24 weeks for Schizophrenia (169)\u003cbr\u003e\n↑ 3.3 pounds average in 6 weeks for Schizophrenia (198, 199)\u003cbr\u003e\n↑ 2.2 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 28 % of people gain ↑ 7 % or more of their baseline weight in \u0026gt; greater than 38 weeks p\u0026lt;0.001 study of varied diagnoses (56)\u003cbr\u003e\n↑ 5.06 pounds average in 14 weeks for Schizo-affective disorder (162) \u003cbr\u003e\n↑ 38% people  gained ↑ 7 % or \u0026gt; greater weight in first 6 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.009) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 55% people  gained↑ 7 % or \u0026gt; greater weight in greater than \u0026gt; 38 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.008) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 4.62 pounds average in 10 weeks [Meta-analysis of 81 studies (67)] and (28) \u003cbr\u003e\n↑ 1.76 pounds average vs placebo (no drug) (time not specified) in Meta-analysis study (700)\u003cbr\u003e\n↑ 4.18 to 15.84 pounds in youths taking risperidone (Risperdal) (n=571 youth) (725)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain in Youth with Psychotic and Bipolar Disorders is 6 young people taking risperidone (Risperdal) (Results of 34 head-to-head and placebo controlled trials 725)\u003cbr\u003e\n↑ If 6 Youth take Risperidone at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Risperidone \u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Risperidone  \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551391829,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_56a18f32-3b57-4fb5-87f5-96955ed8159d.jpg?v=1647711367"},{"product_id":"risperdal-m-tab-discontinued","title":"Risperdal M-TAB  (Discontinued)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 8.8 to 12.32 pounds in short term studies of people who had not taken antipsychotic therapy before. (220)\u003cbr\u003e\n↑ 14.52 to 19.58 pounds in long term studies. [Systematic critical reappraisal (220)]\u003cbr\u003e\n↑ 4.62 pounds average in 24 weeks for Schizophrenia (169)\u003cbr\u003e\n↑ 3.3 pounds average in 6 weeks for Schizophrenia (198, 199)\u003cbr\u003e\n↑ 2.2 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 28 % of people gain ↑ 7 % or more of their baseline weight in \u0026gt; greater than 38 weeks p\u0026lt;0.001 study of varied diagnoses (56)\u003cbr\u003e\n↑ 5.06 pounds average in 14 weeks for Schizo-affective disorder (162) \u003cbr\u003e\n↑ 38% people  gained ↑ 7 % or \u0026gt; greater weight in first 6 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.009) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 55% people  gained↑ 7 % or \u0026gt; greater weight in greater than \u0026gt; 38 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.008) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 4.62 pounds average in 10 weeks [Meta-analysis of 81 studies (67)] and (28) \u003cbr\u003e\n↑ 1.76 pounds average vs placebo (no drug) (time not specified) in Meta-analysis study (700)\u003cbr\u003e\n↑ 4.18 to 15.84 pounds in youths taking risperidone (Risperdal) (n=571 youth) (725)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain in Youth with Psychotic and Bipolar Disorders is 6 young people taking risperidone (Risperdal) (Results of 34 head-to-head and placebo controlled trials 725)\u003cbr\u003e\n↑ If 6 Youth take Risperidone at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Risperidone \u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Risperidone  \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551457365,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_9e13823e-cbe6-4624-b7d6-8db190e5d860.jpg?v=1647711369"},{"product_id":"risperidone-m-tab-discontinued","title":"Risperidone M-TAB (Discontinued)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 8.8 to 12.32 pounds in short term studies of people who had not taken antipsychotic therapy before. (220)\u003cbr\u003e\n↑ 14.52 to 19.58 pounds in long term studies. [Systematic critical reappraisal (220)]\u003cbr\u003e\n↑ 4.62 pounds average in 24 weeks for Schizophrenia (169)\u003cbr\u003e\n↑ 3.3 pounds average in 6 weeks for Schizophrenia (198, 199)\u003cbr\u003e\n↑ 2.2 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 28 % of people gain ↑ 7 % or more of their baseline weight in \u0026gt; greater than 38 weeks p\u0026lt;0.001 study of varied diagnoses (56)\u003cbr\u003e\n↑ 5.06 pounds average in 14 weeks for Schizo-affective disorder (162) \u003cbr\u003e\n↑ 38% people  gained ↑ 7 % or \u0026gt; greater weight in first 6 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.009) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 55% people  gained↑ 7 % or \u0026gt; greater weight in greater than \u0026gt; 38 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.008) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 4.62 pounds average in 10 weeks [Meta-analysis of 81 studies (67)] and (28) \u003cbr\u003e\n↑ 1.76 pounds average vs placebo (no drug) (time not specified) in Meta-analysis study (700)\u003cbr\u003e\n↑ 4.18 to 15.84 pounds in youths taking risperidone (Risperdal) (n=571 youth) (725)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain in Youth with Psychotic and Bipolar Disorders is 6 young people taking risperidone (Risperdal) (Results of 34 head-to-head and placebo controlled trials 725)\u003cbr\u003e\n↑ If 6 Youth take Risperidone at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Risperidone \u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Risperidone  \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551490133,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_ac4be4ec-8ae5-4206-9daa-0e55a13639b3.jpg?v=1647711371"},{"product_id":"risperidone-generic","title":"Risperidone (Generic)","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 8.8 to 12.32 pounds in short term studies of people who had not taken antipsychotic therapy before. (220)\u003cbr\u003e\n↑ 14.52 to 19.58 pounds in long term studies. [Systematic critical reappraisal (220)]\u003cbr\u003e\n↑ 4.62 pounds average in 24 weeks for Schizophrenia (169)\u003cbr\u003e\n↑ 3.3 pounds average in 6 weeks for Schizophrenia (198, 199)\u003cbr\u003e\n↑ 2.2 pounds weight gain per month. [(Systematic review of 34 years of literature (4)]\u003cbr\u003e\n↑ 28 % of people gain ↑ 7 % or more of their baseline weight in \u0026gt; greater than 38 weeks p\u0026lt;0.001 study of varied diagnoses (56)\u003cbr\u003e\n↑ 5.06 pounds average in 14 weeks for Schizo-affective disorder (162) \u003cbr\u003e\n↑ 38% people  gained ↑ 7 % or \u0026gt; greater weight in first 6 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.009) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 55% people  gained↑ 7 % or \u0026gt; greater weight in greater than \u0026gt; 38 weeks of therapy if Risperidone was the 1st antipsychotic medication taken (p 0.008) in study of varied diagnoses [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 4.62 pounds average in 10 weeks [Meta-analysis of 81 studies (67)] and (28) \u003cbr\u003e\n↑ 1.76 pounds average vs placebo (no drug) (time not specified) in Meta-analysis study (700)\u003cbr\u003e\n↑ 4.18 to 15.84 pounds in youths taking risperidone (Risperdal) (n=571 youth) (725)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain in Youth with Psychotic and Bipolar Disorders is 6 young people taking risperidone (Risperdal) (Results of 34 head-to-head and placebo controlled trials 725)\u003cbr\u003e\n↑ If 6 Youth take Risperidone at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gain over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Risperidone \u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Risperidone  \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979551555669,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_4be1e64a-9f1d-4b93-adc8-db1259781458.jpg?v=1647711373"},{"product_id":"abilify-ca","title":"Abilify CA","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979683119189,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_bcd88bf1-c9ce-4df1-98d8-0ea6f2660fb4.jpg?v=1647713792"},{"product_id":"abilify-maintena-ca","title":"Abilify Maintena CA","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979683184725,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_9c3522aa-cdd5-4ee4-9ae2-b49d35501523.jpg?v=1647713794"},{"product_id":"apo-aripiprazole-ca","title":"APO-Aripiprazole CA","description":"\u003cp\u003eWHAT ARE THE EFFECTS OF THIS DRUG?\u003cbr\u003e\n↑ 1.54 pounds average in 4-6 weeks for 10 mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 2.64 pounds average in 4-6 weeks for 20mg\/day dose in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 1.1 pounds avg. in 4-6 weeks for 30mg\/day dose, in 4 weeks in schizophrenia or schizoaffective disorder (199)\u003cbr\u003e\n↑ 26% of people taking Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 if Aripiprazole was the first antipsychotic medication they took. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ 21% of people who took Aripiprazole gained 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001. [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight gain is 20 adults taking Aripiprazole  (1557, 1560)\u003cbr\u003e\n↑ If 20 Adults take Aripiprazole at least one will experience greater than 7% weight gain. (1557, 1560)\u003cbr\u003e\n↑ NNH (Number Needed to Harm) for 7% weight Gain in Youth with Psychotic and Bipolar Disorders is 39 young people taking aripiprazole (Abilify) (725)\u003cbr\u003e\n↑ If 39 Youth take Aripiprazole at least one will experience greater than 7% weight gain. (725)\u003cbr\u003e\n↑ 0 to 9.68 pounds in youths taking aripiprazole (Abilify) (n=451 youth). (725)\u003cbr\u003e\n↑ “Antipsychotic-related weight gain and metabolic adverse effects have become a major focus, especially in youth.  Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for obesity by 2.28X (2.28 times) in children and adolescents. (725)\u003cbr\u003e\n↑ Antipsychotic polypharmacy (taking 2 or more antipsychotic drugs together) increased the risk for any heart disease event, cerebrovascualar event (like stroke), or high blood pressure adverse events by 1.72X greater risk (1.72 times increased risk) in children and adolescents. (725)\u003cbr\u003e\n↑ “However, despite marked weight gain and its greater impact on youth, monitoring rates are low and studies of pharmacologic and behavioral interventions are extremely limited.” Results of 34 head-to-head and placebo controlled trials (725)\u003cbr\u003e\n↑ 72% of people taking 2nd generation antipsychotics gain 7% or more of their baseline weight in greater than \u0026gt; 38 weeks p\u0026lt;0.001 [Meta-analysis of 307 studies (56)]\u003cbr\u003e\n↑ Virtually all antipsychotic medications are associated weight gained over time. [Meta-analysis of 307 studies (56)] and [Meta-analysis of 81 studies (67)] and (2200, 2190, 2208)\u003cbr\u003e\n↑ Both 1st and 2nd generation antipsychotics are associated with weight gain. [Meta-analysis of 81 studies (67)]\u003cbr\u003e\nGeneric Name:  Aripiprazole\u003c\/p\u003e","brand":"WeightGainDrugs.com","offers":[{"title":"Aripiprazole \/ Buy the eBook to learn the hormone and appetite influences. \/ Order the eBook to discover possible alternative drugs.","offer_id":39979683250261,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/1423\/products\/weightGainDrugs_front_0240b9ff-8fa9-4893-b642-2d4fd0aa4ac9.jpg?v=1647713796"}],"url":"https:\/\/www.weightgaindrugs.com\/collections\/antipsychotic-mood-2nd-generation.oembed","provider":"Weight Gain Drugs","version":"1.0","type":"link"}